Pennside Partners Welcomes New European Director

Posted by Tom Penrice on Mon,Feb 20, 2017 @ 06:34 PM

Tom Perkins joins Pennside Partners, a pharma and biotech consulting firim, as European Director.Pennside Partners extends a warm welcome to Tom Perkins, who has been hired as a Director based out of our Zurich office. Tom brings 14 years of pharmaceutical consulting experience to Pennside. Tom is joining Pennside after more than a decade with leading market research firm, GfK. He began his pharma career first as an intern at V2 (acquired by GfK) during his studies at St. Joseph’s University (Philadelphia, PA, United States). He then quickly advanced through the organization to become a Division Manager of GfK’s Swiss arm based in Basel, Switzerland where he was the key account manager for one of GfK’s top clients.


Tom brings vast expertise in respiratory conditions (COPD, PAH, Cystic Fibrosis) and previous experience in oncology and hematology. In his last 3 years with GfK, Tom was running launch tracking for a major respiratory player. Previously, he was the project leader for the largest primary market research program ever conducted in Type 2 Diabetes where over 6,000 physicians and 10,000 patients from 26 countries gave insights on physician communication and marketing. Publications regarding this Diabetes project are forthcoming in 2017.


“We are excited to have Tom join our team. He will be an integral part of our plans to expand our European presence while continuing to provide excellent service to our existing client base. Our recent staff additions as well as the opening of our Manchester, UK area office in May of 2016 demonstrate our commitment to delivering the highest quality business development support, strategy, and competitive intelligence services to the pharmaceutical and biotech industries on a global scale,” said Tom Penrice, VP and Co-Founder of Pennside Partners.

For more information, including how Pennside can help you with your business development and competitive intelligence needs, contact Pennside Partners at 610-372-7000 or consult@pennside.com.

Pennside Partners EU Headquaters in Zurich, Switzerland, from which Pennside's new European Director will serve Pennside's pharmaceutical and biotech clients.Pennside’s Zurich office is located at Balsberg, Balz Zimmermann Strasse 7, CH-8058 Zurich-Flughafen, Switzerland and can be reached at +41 79 372 7070. You may also visit the company website: www.pennside.com.


About Pennside Partners

Pennside Partners is a leading business development consulting firm that has been serving the global pharmaceutical, biotechnology, and medical device sectors for more than 25 years. We earn our clients’ trust by consistently delivering high quality, actionable business insights and competitive intelligence. Our clients gain significant competitive advantages, including knowledge we acquire from mining the industry's deepest analog repository containing unmatched data insights into major launches. We offer an expert worldwide team of industry professionals who support our clients by formulating best-in-class tactical and strategic analysis. 


Pennside Partners is a leading pharmaceutical and biotech consulting firm with over 25 years experience. They are headquartered in the United States, the United Kingdom and Switzerland.

Tags: Pharma Consulting, Biotech Consulting

Pennside Partners, Ltd. Celebrates 25th Anniversary

Posted by Tom Penrice on Mon,Nov 30, 2015 @ 09:00 AM

Pennside Partners, Ltd. is a leading business development consulting firm serving the pharmaceutical, biotechnology, and medical device sectors worldwide.

This year Pennside Partners celebrates over 25 years of being a trusted partner within the pharma and biotech industries.

At Pennside, we have gained our client’s trust by consistently delivering high-quality, actionable business insight and competitive intelligence. Our mission is to help our pharma and biotech clients rapidly formulate winning strategies and tactics by providing the industry’s most accurate business intelligence and market insight. With headquarters in both the United States and Switzerland, we are able to quickly and thoroughly respond to the unique needs of each client worldwide.

What Pennside Partners, Ltd. Offers

Pennside Partners, Ltd. provides of the following services:

  • Competitive benchmarking
  • Therapeutic category monitoring
  • Developmental pipeline analysis
  • Brand strategy support
  • New commercial models
  • Pricing & reimbursement
  • Technology due diligence
  • War games and strategy
  • Manufacturing cost analysis
  • Clinical/ regulatory strategy
  • OTC drugs and Rx switch
  • Orphan / rare drug launch
  • Business Development

Pennside Partners, Ltd. can provide insight to these therapeutic categories of interest:

  • Oncology
  • Orphan / rare disease
  • Cardiovascular
  • CNS
  • Endocrinology/ Diabetes
  • Respiratory
  • Anti-infective
  • Dermatology
  • Gastro-intestinal
  • Nephrology
  • Neurology
  • Ophthalmology
  • Rheumatology & bone health
  • Urology
  • Vaccines
  • Women’s health



What is in store for Pennside Partners, Ltd.

In the weeks and months ahead we plan to devote considerable energy to addressing key biotechnology and pharmaceutical industry topics of interest, including:

  • Prelaunch and launch planning
  • Launch analogs
  • Business development
  • Brand strategy
  • Benchmarking
  • Competitive intelligence (CI) and monitoring
  • Pipeline analysis
  • Disease landscape
  • Licensing and acquisition


 

Meet Pennside’s Team

Michael A. Rhoads, President and Co- founder

Mike has 25 years of experience as a consultant to the global pharmaceutical industry. He has managed over 300 competitive clinical benchmarking assignments since 1990. Under his supervision, the Pennside medical staff has completed a variety of strategic and tactical assessments covering all major therapeutic categories. As Director of the Clinical Strategies Group within Pennside, he personally directed multiple clinical CI programs in various therapeutic categories. Mike is one of the earliest participants in the Society of Competitive Intelligence Professionals (SCIP), and an acknowledged expert in the field of competitive clinical intelligence. He has delivered numerous keynote addresses at SCIP annual meetings and was selected to conduct two specific educational workshops for the drug industry in recent years.

Mike earned his MBA from the Wharton School of Business at the University of Pennsylvania and a B.A. from Colgate University.

Thomas J. Penrice, Vice President and Co- founder of Pennside Partners, Ltd.

Tom has over 25 years of experience in the pharmaceutical industry. As a pharmaceutical industry consultant since 1986, he has conducted and managed hundreds of projects in most major disease states and numerous drug delivery technologies.

Tom earned his MBA from the Advanced Management Program at Michigan State University and a B.S. in chemistry from Marquette University.

Anthony Arleth, Managing Director US

Tony has over 20 years of experience in the pharmaceutical industry. He spent 21 years at GlaxoSmithKline, with extensive experience in business opportunity analysis. He began his career as a bench scientist and is a trained biochemist / molecular pharmacologist. He brings a wide range of industry knowledge to Pennside, with specialization in the Cardiovascular, Oncology, and Pharmacogenetic areas.

Tony earned his undergraduate degree from Villanova University and conducted graduate work at the University of Pennsylvania and Villanova University

Eric Vaichunas, M.D., MHSA, Medical Director

Eric has over four years of clinical experience in general medicine. Over the course of his experience, he was involved in various aspects of the internal medicine field with several key opinion leaders at Michael Reese Hospital, Chicago, IL, St. Vincent’s Hospital, New York, NY; and Mount Sinai School of Medicine, New York, NY.

Eric earned his M.D. from St. Matthew’s School of Medicine, his M.S. in Health Service Administration from St. Joseph’s College of Maine, and his B.S. in Biomedical Science from Hahnemann University. Eric completed a year of graduate work in Biomedical Science at the Philadelphia College of Osteopathic Medicine.


 

Contact Us!

Contact Pennside Partners, a leading pharma and biotech consulting firm, at our US or EU headquarters.

To learn more about the advantages of our leading strategic consulting services contact our US or EU offices:

US: +1 610 372 7000

UK: +44 20 3695 7639

Switzerland: +41 79 372 7070

Contact Pennside Partners for all your pharma and biotech consulting needs


Pennside Partners is a leading pharmaceutical and biotech consulting firm with over 25 years experience. They are headquartered in the United States, the United Kingdom and Switzerland.

Tags: Pharma Consulting, Biotech Consulting, Press Releases

Orphan Diseases Open Opportunity for Pharma, Biotech Drug Developers

Posted by Shannon Flynn on Sat,Feb 23, 2013 @ 09:00 AM

Orphan Diseases Attract Increasing Attention Across the Board

The lack of FDA-approved orphan drugs represents a significant economic opportunity for pharma and biotech drug development firmsAs patents expire and generic competition increases, more drug companies are investing in the development of therapeutics for orphan diseases. Although the pool of patients for an orphan disease is small, the economic potential of an expensive biologic administered over the lifetime of a limited number of patients presents an attractive commercial opportunity that is a savvy alternative to the en mass selling of lower-priced small molecule compounds which are the mainstay of the industry.

Pharma / Biotech Economics: 7,000 Orphan Diseases, 200 Treatments

Thomson Reuters reports that in the U.S. alone, rare diseases afflict an estimated 25 million people, representing approximately 8% of the total population[i]. According to the National Organization for Rare Disorders (NORD) nearly 7,000 orphan diseases have been categorized already and that number continues to grow year by year as new discoveries are made. Nevertheless, only about 200 of these have FDA approved treatments, leaving the market wide-open to newcomers.

In 2011, orphan drugs represented one third of NMEs approved by the FDA. The same year the orphan drug market was estimated at over $50 billion, accounting for roughly 6% of all pharmaceutical sales. In 2012, approximately one quarter of the 39 new drugs approved by the FDA had orphan status. This pattern continues, as a recent analysis reports that nearly 1,800 of the 5,400 drugs currently in development have received orphan status[ii].

In addition to tantalizing premium prices, which can range from $100,000 to over $400,000 per patient annually, growth is driven by government incentives including tax credits, grants, and regulatory fee waivers as well as shortened approval times and higher probability of approval. Faster uptake, lower marketing costs and longer market exclusivity are also key drivers of growth. In addition, patient organizations often raise funds for research, lowering R&D spend.

Hurdles to Drug Development

Though the lucrative profit potential of these drugs is alluring, success in the orphan market is not without its own set of challenges. Lack of education and awareness among patients and providers alike, along with sometimes poor diagnostic methods hinders identification of the target patient population. Rare disorders are often cryptic, leaving patients misdiagnosed or undiagnosed for long periods of time which can span many years. For example, it is not uncommon for patients suffering with Hereditary Angioedema (HAE) to wait up to 10 years before receiving an accurate diagnosis[iii].

Locating and recruiting patients poses logistical problems to organizing and carrying out clinical trials, resulting in increased costs. Nevertheless, companies have proven successful in overcoming these obstacles and expanding the patient population through utilizing social media, engaging patient advocacy groups and spearheading awareness campaigns and educational programs.

While the economic burden of leaving the population untreated typically outweighs the costs of treatment due to improved patient outcomes, as interest in high-priced, specialty drugs continues to grow, so does the potential for payer pushback. At present, the jaw-dropping costs are largely covered by government programs, health plans and company-sponsored payment assistance programs in order to ensure access to affordable care for patients.

Nevertheless, as patient phenotyping and personalized medicine further characterize more common diseases into specific indications, the number of diseases that meet the criteria for orphan status will continue to expand, placing even greater burden on the healthcare system.

Worthwhile Opportunity for Pharma and Biotech Drug Developers for the Foreseeable Future

For the moment however, it appears the benefits of orphan drug development far outweigh the cost for industry and payers alike, creating a stable and growing market ripe with opportunity.

 


[i] “The Economic Power of Orphan Drugs” Thomson Reuters Report, Aug 2012

[ii] “Innovation in the Biopharmaceutical Pipeline: A multi-dimensional view” Analysis Group, Jan 2013

[iii]  Lunn, M. L., C. B. Santos, and T. J. Craig. "Is There a Need for Clinical Guidelines in the United States for the Diagnosis of Hereditary Angioedema and the Screening of Family Members of Affected Patients?" Annals of Allergy Asthma & Immunology 104.3 (2010): 211-14.


Pennside Partners is a leading pharmaceutical and biotech consulting firm with over 25 years experience. They are headquartered in the United States, the United Kingdom and Switzerland.

Tags: Drug Development, Pharma Consulting, Biotech Consulting, Orphan Drug Development

ASCO GU: Heads-Up for Biotech Drug Development in Kidney Cancer

Posted by Marne Wessner on Mon,Feb 11, 2013 @ 11:50 PM

Interesting Data for Pharma and Biotech Drug Developers

ASCO GU2 2013 Genitourinary Cancers Symposium for Pharma and Biotech Drug DevelopmentASCO’s second meeting of the year, ASCO GU, is coming up next week, and here is our list of anticipated data releases for renal cell carcinoma.  (Note that full abstracts won’t be available until February 12, so it is impossible to comment on the significance of these results until then.) It looks to be a quiet meeting this year for RCC, according to key opinion leaders, but there are some presentations on the schedule with the potential for interesting data for Pharma and Biotech drug developers.

Additional Data from TIVO-1 Trial of Aveo/Astellas’ Tivozanib

There are several abstracts reporting aspects of the TIVO-1 trial data at this year’s meeting. OS, subgroup analyses, and quality of life data are of high interest, and two additional poster presentations will also address biomarker research and tivozanib efficacy in patients previously treated with Bayer’s Nexavar (sorafenib).

Emerging Immunotherapies

Immunotherapy is an exciting field in RCC. The latest generation of immunomodulating agents includes nivolumab, an anti-PD1 from BMS; and AGS-003, a dentritic cell therapy from Argos—both in Ph III for RCC. These agents each have poster presentations, which will hopefully give early indications about their potential in RCC.

Sequencing and Combinations of Approved Therapies for Kidney Cancer

The hottest issue in RCC therapeutics is the sequencing of the many approved agents on the market, and the positioning of any new ones about to be approved. This is a conundrum for oncologists as well as drug developers seeking to leverage the data to gain market share.

  • Votrient: Additional quality of data from the COMPARZ trial of GSK’s Votrient (pazopanib) vs. Pfizer’s Sutent (sunitinib) in first line RCC will report, likely an update of what was reported at ESMO 2012 last fall.
     
  • Inlyta:  Pfizer announced that the AGILE 1051 trial of Inlyta (axitinib) in first line RCC did not meet its primary endpoint in October 2012, and it looks like we will finally see data from that trial as well as the Ph II dosing trial in first line RCC.
     
  • Avastin combos: The Ph II BEST trial, which compared Roche/Genentech’s Avastin alone and combinations of Avastin, Nexavar, and Torisel, will also report data. In RCC, combinations of currently-approved targeted agents have been unsuccessful historically, so expectations are low for this trial.
     
  • mTOR inhibitors: Finally, a new safety analysis of mTOR inhibitors will be presented, which will hopefully provide oncologists with more information on dealing with the side effects of this class of drugs, which are very different from the tyrosine kinase inhibitors that are commonly used in RCC.

 

Key Presentations of Interest at ASCO GU

  1. Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with RCC (Motzer, et al, abstract 350)
     
  2. Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with mRCC (Hutson, et al, abstract 354)
     
  3. Treatment benefit of tivozanib hydrochloride versus sorafenib on health-related quality of life among patients with advanced/mRCC: Tivo-1 study results (Cella, et al, abstract 355)
     
  4. Axitinib vs. sorafenib as first‑line therapy in patients with mRCC (Hutson, et al, abstract LBA348)
     
  5. Quality of life among patients with RCC treated with pazopanib versus sunitinib in the COMPARZ study (Cella, et al, abstract 346)
     
  6. Axitinib with or without dose titration for first-line mRCC: Unblinded results from a randomized phase II study (Rini et al, abstract LBA349)
     
  7. The BEST trial (E2804): A randomized Ph II study of VEGF, RAF kinase, and mTOR combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced RCC (McDermott et al, abstract 345)
     
  8. Incidence and risk of treatment-related mortality in patients with RCC and non-RCC treated with mTOR inhibitors (Choueiri, et al, abstract 347)
     
  9. Clinical activity and safety of antiPD-1 (BMS-936558) in patients with previously treated mRCC: An updated analysis (McDermott, et al, abstract 351)
     
  10. Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk mRCC (Amin, et al, abstract 357)


Pennside Partners is a leading pharmaceutical and biotech consulting firm with over 25 years experience. They are headquartered in the United States, the United Kingdom and Switzerland.

Tags: Drug Developers, Targeted Therapy, Drug Development, Kidney Cancer, Biotech Consulting, Pharma Launch Planning

ASCO GI Preview - Heads Up for GI Cancer Drug Development

Posted by Marne Wessner on Tue,Jan 15, 2013 @ 08:00 AM

ASCO GI Cancer Drug Development

Abstract titles are up for ASCO GI, and here’s a list of the abstracts we are looking forward to seeing next week.  (Note that full abstracts won’t be available until January 22, so it is impossible to comment on the significance of these results until then.)

Abraxane positive in phase III for pancreatic cancer

The Abraxane study in pancreatic cancer (abstract 67) is likely to be the major news from this year’s meeting. At ESMO in October, KOLs were indicating that the results might be positive, and indeed, Celgene announced in November that this trial met its primary endpoint of overall survival with a statistically significant improvement over gemcitabine alone. Now we will finally see the data. There have been so many notable failed trials in this disease (axitinib and ganitumab, for example) that it’s exciting to finally see something positive!

New biomarker and safety data for Stivarga (regorafenib)

Bayer’s Stivarga was just approved for third line CRC in September 2012, and presentations at this meeting include biomarker and safety data (abstracts 318 and 467). Hopefully the new data will shed light on which patients are most suitable for Stivarga and how oncologists can deal with toxicities.

Ramucirumab data notably absent

We also note that the phase III gastric cancer trial of ramucirumab (VEGF inhibitor, Lilly), which was announced as positive a few months ago, will not be presented. The next opportunity to present the data at an important venue will be at the main ASCO meeting in June.

New GI cancer drugs on the horizon at last

KOLs have been complaining that there hasn’t been anything new in CRC for a long time, but it looks like the tide is finally turning with two new approvals in 2012, and some promising new agents on the horizon. All of these developmental agents could eventually make an impact in standards of care for CRC.

In HCC, there are a few developmental agents with early-phase data that will be presented. Of note is the Pfizer CDK inhibitor, PD-0332991, in HCC. Last month at SABCS, this agent reported very promising phase II efficacy data in ER+ breast cancer, as well as a mild toxicity profile. Efficacy combined with good tolerability could make it an attractive compound in HCC.

 

Key presentations of interest for drug development at ASCO GI

  1. Final results of a randomized phase III study of weekly nab-paclitaxel [Abraxane] plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (Von Hoff, et al, abstract LBA148)
  2. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib (Jeffers et al, abstract 381)
  3. Time course of regorafenib-associated adverse events in the Ph III CORRECT study (Grothey, et al, abstract 467)
  4. Ph II study of PD-0332991 in advanced HCC (Littman, et al, abstract 321)
  5. Patient-reported outcomes from a phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib  (Dutton, et al, abstract 6)
  6. Ph II study of vismodegib, a hedgehog pathway inhibitor, combined with FOLFOX in patients with advanced GaCa and GEJ: A NY cancer consortium led study (Cohen, et al, abstract 67)
  7. A randomized, double-blind, placebo-controlled trial of trametinib in combination with gemcitabine for untreated metastatic PnCa (Infante, et al, abstract 291)
  8. Ph I/II study of golvantinib in combination with sorafenib in patients with advanced HCC: Ph I results (O’Neil, et al, abstract 294)
  9. Long-term efficacy and pharmacodynamic parameter analysis in pretreated KRAS-mutant mCRC patients treated with RG7160 (GA201), an ADCC-enhanced monoclonal anti-EGFR antibody (Delord, et al, abstract 379)
  10. Second-line therapy of KRAS-mutated mCRC with the MEK inhibitor selumetinib in combination with irinotecan: An AGICC study (Hochster, et al, abstract 380)

 


Pennside Partners is a leading pharmaceutical and biotech consulting firm with over 25 years experience. They are headquartered in the United States, the United Kingdom and Switzerland.

Tags: Drug Development, Biotech Consulting, Competitive Intelligence, Gastrointestinal Cancer, GI Drug Development

Welcome to Pharma & Biotech Today

Posted by Tom Penrice on Mon,Jan 07, 2013 @ 04:59 PM

Welcome to Pharma & Biotech Today, the blog for pharmaceutical and biotechnology industry professionals. Our goal is to provide you with thought-provoking articles and opinions to assist you in moving your pharma or biotech firm to the forefront in today's competitive market and ever-changing landscape.

Trusted pharma and biotech consulting industry services for over 20 years - Pennside Partners.20 Years Experience -
A Wealth of Information to Share 

With over 20 years in the pharma and biotech consulting business, we have a wealth of information and experience to share with you, our valued readers and subscribers.

In the weeks and months ahead we plan to devote considerable energy to addressing key biotechnolgoy and pharmaceutical industry topics of interest, including:

    • Prelaunch and launch planning and best practices
    • Launch analogs
    • Business development
    • Brand strategy
    • Benchmarking
    • Competitive intelligence (CI) and monitoring
    • Pipeline analysis
    • Disease landscape
    • Licensing and acquisition
    • Market insight
    • ... and many more!

Pharmaceutical and Biotechnology consulting experts - Pennside PartnersWe Want to Hear From You!

Tell us about any topics that interest you in today's fast-paced and ever-changing pharma and biotech fields. We'll look forward to addressing many of them in upcoming articles. We'd love to hear from you soon - just click to contact us any time.

Finally, please bookmark this site and check back often for the latest in pharma and biotech news, information, and thought leadership. 


Pennside Partners is a leading pharmaceutical and biotech consulting firm with over 25 years experience. They are headquartered in the United States, the United Kingdom and Switzerland.

Tags: Pharma Brand Strategy, Pharma Consulting, Biotech Consulting, Pharma Launch Planning, Competitive Intelligence, Pipeleine Analysis, Pharma Launch Analogs

Receive Blog Posts by Email

Follow Us

Learn More About Our Services

Learn more about Pennside's pharma war games, strategy workshops, and competitive simulations for the pharma and biotech industries


Learn more about Pennside's pharma launch analog services, including pharma business development, pharma benchmarking, pharma best practices, pharma business analytics, business intelligence, ci, competitive intelligence, pharma launch planning, and other strategic consulting services for the pharmaceutical industry. 

Learn more about Pennside's  pharmaceutical and biotechnology consulting services spanning the following areas: competitive intelligence and monitoring, pipeline analysis and disease landscape consulting, marketing/sales/reimbursement support benchmarking, launch support and best practices benchmarking, customer facing and new commercial models, licensing and support consulting, strategy workshops, and outsourced business intelligence and fixed term contractors consulting for the pharma and biotech industries. 

Learn more about Pennside's Robust Pharma Competitive Intelligence and CI Monitoring Services. We provide superior pharma strategies based on actionable corporate intelligence. 

Learn more about our Oncology Drug Development Support Services: oncology launch analog service, oncology congress coverage service, post-launch intelligence and market monitoring, oncology business development and licensing and M&A support, and tumor/MOA clinical pipeline analysis services. Oncology launch adoption and market strategy services include: launch planning support, primary field intelligence and market insights, oncology competitive pipeline analysis, inlicensing reviews, oncology biomarker analysis, and benchmarking of oncology organizations. Oncology Congress Coverage services include: preparing a targeted congress schedule, attending and capturing key oncology conference information, and presenting oncology conference findings.

Contact Us or Request Information

Experience You Can Trust

Trusted pharma and biotech consulting experts for over 25 years